Literature DB >> 6439437

Contrasting effects of subcutaneous pulsatile GnRH therapy in congenital adrenal hypoplasia and Kallmann's syndrome.

D Gordon, H N Cohen, G H Beastall, I D Hay, J A Thomson.   

Abstract

A patient with congenital adrenal hypoplasia (AH) and hypogonadotrophic hypogonadism was treated with pulsatile subcutaneous GnRH therapy for 16 weeks in an attempt to induce puberty. No rise in serum LH or FSH concentrations occurred despite increasing doses of GnRH (2.8 micrograms/pulse-22.4 micrograms/pulse). In contrast a similar programme of therapy successfully initiated the biochemical changes of puberty in a patient with Kallmann's syndrome. Both patients before therapy had low basal serum LH and FSH concentrations with blunted LH and FSH responses to GnRH stimulation. After 1 week, serum LH and FSH rose into the normal adult range in the patient with Kallmann's syndrome. This study fails to confirm a previous report which suggested that intermittent low dose GnRH therapy may be of value in inducing puberty in AH. The reasons for the difference of pituitary responsiveness to GnRH in AH and Kallmann's syndrome are unclear at present.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439437     DOI: 10.1111/j.1365-2265.1984.tb01401.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Update on pulsatile luteinizing hormone-releasing hormone therapy in males with idiopathic hypogonadotropic hypogonadism and delayed puberty.

Authors:  M Giusti; P Cavagnaro
Journal:  J Endocrinol Invest       Date:  1991-05       Impact factor: 4.256

Review 2.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

3.  DAX1 mutations map to putative structural domains in a deduced three-dimensional model.

Authors:  Y H Zhang; W Guo; R L Wagner; B L Huang; L McCabe; E Vilain; T P Burris; K Anyane-Yeboa; A H Burghes; D Chitayat; A E Chudley; M Genel; J M Gertner; G J Klingensmith; S N Levine; J Nakamoto; M I New; R A Pagon; J G Pappas; C A Quigley; I M Rosenthal; J D Baxter; R J Fletterick; E R McCabe
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

4.  Adrenal hypoplasia congenita with hypogonadotropic hypogonadism: evidence that DAX-1 mutations lead to combined hypothalmic and pituitary defects in gonadotropin production.

Authors:  R L Habiby; P Boepple; L Nachtigall; P M Sluss; W F Crowley; J L Jameson
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

5.  Progressive high frequency hearing loss: an additional feature in the syndrome of congenital adrenal hypoplasia and gonadotrophin deficiency.

Authors:  M Zachmann; E Fuchs; A Prader
Journal:  Eur J Pediatr       Date:  1992-03       Impact factor: 3.183

6.  Lack of gonadotropic response to pulsatile gonadotropin-releasing hormone in isolated hypogonadotropic hypogonadism associated to congenital adrenal hypoplasia.

Authors:  P Bovet; M J Reymond; F Rey; F Gomez
Journal:  J Endocrinol Invest       Date:  1988-03       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.